Wednesday, June 28, 2023 Please be advised that the CCTG CO27 Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-Risk Stage III Colon Cancer in Adjuvant Setting has closed to accrual having met the accrual target. The primary objective for the study is 3 year Disease Free Survival (DFS) Secondary Objectives: 2 year DFS, Overall Survival, safety of study treatment. For more information please visit the CCTG CO27 members trial page.
